Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era
Paul J. Hampel(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Rebecca L. King(Mayo Clinic in Arizona), Min Shi(Mayo Clinic in Arizona), Tait D. Shanafelt(Mayo Clinic), Ricardo Parrondo(Jacksonville College), Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic in Arizona), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Cinthya Zepeda‐Mendoza(Mayo Clinic in Arizona), Steven R. Hwang(Mayo Clinic), Susan L. Slager(Mayo Clinic), Talal Hilal(WinnMed), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Esteban Braggio(Dana-Farber Cancer Institute), Yucai Wang(Mayo Clinic), Curtis A. Hanson(Mayo Clinic in Arizona), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Mazie Tsang(Mayo Clinic Hospital)
Cited by 12
Related Papers
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Changes in Burnout and Satisfaction With Work-Life Integration in Physicians and the General US Working Population Between 2011 and 2017
|Mayo Clinic Proceedings|2019|903
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735